Mymetics

Mymetics ROCE

The Return on Capital Employed (ROCE) of Mymetics (MYMX) as of Oct 16, 2026 is 2.69 %. In the previous year, Return on Capital Employed (ROCE) was 2.75 % — a change of -2.08% (lower).

ROCE

2.69 %

YoY

-2.08%

Last updated:

In 2022, Mymetics's return on capital employed (ROCE) was 2.69 %, a -2.08% increase from the 2.75 % ROCE in the previous year.

The Mymetics ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2015
0.55 EUR
Jan 1, 2016
2.69 EUR
Jan 1, 2017
4.27 EUR
Jan 1, 2018
2.97 EUR
Jan 1, 2019
2.91 EUR
Jan 1, 2020
2.84 EUR
Jan 1, 2021
2.75 EUR
Jan 1, 2022
2.69 EUR
The Mymetics ROCE history
YEARROCEYoY
2.69 %-2.08%
2.75 %-3.43%
2.84 %-2.36%
2.91 %-1.90%
2.97 %-30.48%
4.27 %+58.77%
2.69 %+388.76%
0.55 %-70.27%
1.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mymetics Stock analysis

What does Mymetics do? Mymetics Corp, listed under the ticker MYMX with ISIN US62856A3005, is a biotechnology company based in Epalinges, Switzerland. The company operates within the Health Care sector, specifically in the Biotechnology industry. Mymetics Corp has an employee count of 8 and went public on February 10, 1995. The company's website is https://www.mymetics.com/. Mymetics Corp focuses on the research and development of virosome-based vaccines for infectious diseases. Virosomes are lipid-based carriers that incorporate functional fusion viral proteins and natural membrane proteins, combined with rationally designed antigens. The company has multiple vaccine candidates in its pipeline, including those targeting HIV-1/AIDS, influenza, malaria, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). The HIV-1 vaccine candidate utilizes virosomes linked to conserved antigens derived from HIV-1 glycoprotein 41 (gp41) proteins of clade B. The RSV vaccine candidate is composed of reconstituted RSV membrane containing native viral proteins. Similarly, the HSV vaccine candidate consists of reconstituted membranes from HSV-1 or HSV-2, while the intranasal influenza vaccine includes reconstituted influenza virus membranes. Mymetics Corp's technology aims to develop prophylactic vaccines through these virosome-based approaches. The company's headquarters are located in Epalinges, Vaud, Switzerland. The firm's current focus is on advancing its pipeline of vaccine candidates for various infectious diseases through innovative virosome technology. Mymetics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Mymetics's Return on Capital Employed (ROCE)

Mymetics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Mymetics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Mymetics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Mymetics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Mymetics stock

Return on Capital Employed (ROCE) of Mymetics is 2.69 % in 2022.

Return on Capital Employed (ROCE) of Mymetics changed from 2.75 % to 2.69 %, representing a -2.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Mymetics since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Mymetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Mymetics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Mymetics